Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Development and validation of a medium-throughput electrophysiological assay for KCNQ2/3 channel openers using QPatch HT.

Zhang XF, Zhang D, Surowy CS, Yao B, Jarvis MF, McGaraughty S, Neelands TR.

Assay Drug Dev Technol. 2013 Feb;11(1):17-24. doi: 10.1089/adt.2012.446. Epub 2012 Sep 24.

PMID:
23002961
2.

Synthesis and SAR of 4-aminocyclopentapyrrolidines as N-type Ca²⁺ channel blockers with analgesic activity.

Beebe X, Darczak D, Henry RF, Vortherms T, Janis R, Namovic M, Donnelly-Roberts D, Kage KL, Surowy C, Milicic I, Niforatos W, Swensen A, Marsh KC, Wetter JM, Franklin P, Baker S, Zhong C, Simler G, Gomez E, Boyce-Rustay JM, Zhu CZ, Stewart AO, Jarvis MF, Scott VE.

Bioorg Med Chem. 2012 Jul 1;20(13):4128-39. doi: 10.1016/j.bmc.2012.04.057. Epub 2012 May 4.

PMID:
22626552
3.

SAR of α7 nicotinic receptor agonists derived from tilorone: exploration of a novel nicotinic pharmacophore.

Schrimpf MR, Sippy KB, Briggs CA, Anderson DJ, Li T, Ji J, Frost JM, Surowy CS, Bunnelle WH, Gopalakrishnan M, Meyer MD.

Bioorg Med Chem Lett. 2012 Feb 15;22(4):1633-8. doi: 10.1016/j.bmcl.2011.12.126. Epub 2012 Jan 8.

PMID:
22281189
4.

Coexpression and activation of TRPV1 suppress the activity of the KCNQ2/3 channel.

Zhang XF, Han P, Neelands TR, McGaraughty S, Honore P, Surowy CS, Zhang D.

J Gen Physiol. 2011 Sep;138(3):341-52. doi: 10.1085/jgp.201110618. Epub 2011 Aug 15.

5.

Cracking the molecular weight barrier: fragment screening of an aminotransferase using an NMR-based functional assay.

Mendoza R, Petros AM, Liu Y, Thimmapaya R, Surowy CS, Leise WF, Pereda-Lopez A, Panchal SC, Sun C.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5248-50. doi: 10.1016/j.bmcl.2011.07.039. Epub 2011 Jul 21.

PMID:
21840712
6.

KCNQ2/3 openers show differential selectivity and site of action across multiple KCNQ channels.

Zhang D, Thimmapaya R, Zhang XF, Anderson DJ, Baranowski JL, Scanio M, Perez-Medrano A, Peddi S, Wang Z, Patel JR, DeGoey DA, Gopalakrishnan M, Honore P, Yao BB, Surowy CS.

J Neurosci Methods. 2011 Aug 30;200(1):54-62. doi: 10.1016/j.jneumeth.2011.06.014. Epub 2011 Jun 23.

PMID:
21723881
7.

Fibromyalgia: mechanisms, current treatment and animal models.

Brederson JD, Jarvis MF, Honore P, Surowy CS.

Curr Pharm Biotechnol. 2011 Oct;12(10):1613-26. Review.

PMID:
21466451
8.

Comparative analysis of inactivated-state block of N-type (Ca(v)2.2) calcium channels.

Vortherms TA, Swensen AM, Niforatos W, Limberis JT, Neelands TR, Janis RS, Thimmapaya R, Donnelly-Roberts DL, Namovic MT, Zhang D, Brent Putman C, Martin RL, Surowy CS, Jarvis MF, Scott VE.

Inflamm Res. 2011 Jul;60(7):683-93. doi: 10.1007/s00011-011-0322-9. Epub 2011 Mar 11.

PMID:
21394563
9.

A thallium transport FLIPR-based assay for the identification of KCC2-positive modulators.

Zhang D, Gopalakrishnan SM, Freiberg G, Surowy CS.

J Biomol Screen. 2010 Feb;15(2):177-84. doi: 10.1177/1087057109355708. Epub 2010 Jan 19.

PMID:
20086212
10.

Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.

Honore P, Chandran P, Hernandez G, Gauvin DM, Mikusa JP, Zhong C, Joshi SK, Ghilardi JR, Sevcik MA, Fryer RM, Segreti JA, Banfor PN, Marsh K, Neelands T, Bayburt E, Daanen JF, Gomtsyan A, Lee CH, Kort ME, Reilly RM, Surowy CS, Kym PR, Mantyh PW, Sullivan JP, Jarvis MF, Faltynek CR.

Pain. 2009 Mar;142(1-2):27-35. doi: 10.1016/j.pain.2008.11.004. Epub 2009 Jan 9.

PMID:
19135797
11.

Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors.

Wang X, Sarris K, Kage K, Zhang D, Brown SP, Kolasa T, Surowy C, El Kouhen OF, Muchmore SW, Brioni JD, Stewart AO.

J Med Chem. 2009 Jan 8;52(1):170-80. doi: 10.1021/jm801042a.

PMID:
19072118
12.

Elevated temperatures alter TRPV1 agonist-evoked excitability of dorsal root ganglion neurons.

Neelands TR, Jarvis MF, Faltynek CR, Surowy CS.

Inflamm Res. 2008 Sep;57(9):404-9. doi: 10.1007/s00011-008-7223-6.

PMID:
18777111
13.

Tetrahydropyridine-4-carboxamides as novel, potent transient receptor potential vanilloid 1 (TRPV1) antagonists.

Brown BS, Keddy R, Zheng GZ, Schmidt RG, Koenig JR, McDonald HA, Bianchi BR, Honore P, Jarvis MF, Surowy CS, Polakowski JS, Marsh KC, Faltynek CR, Lee CH.

Bioorg Med Chem. 2008 Sep 15;16(18):8516-25. doi: 10.1016/j.bmc.2008.08.005. Epub 2008 Aug 7.

PMID:
18722778
14.

(R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo.

Surowy CS, Neelands TR, Bianchi BR, McGaraughty S, El Kouhen R, Han P, Chu KL, McDonald HA, Vos M, Niforatos W, Bayburt EK, Gomtsyan A, Lee CH, Honore P, Sullivan JP, Jarvis MF, Faltynek CR.

J Pharmacol Exp Ther. 2008 Sep;326(3):879-88. doi: 10.1124/jpet.108.138511. Epub 2008 May 30.

PMID:
18515644
15.

Central pituitary adenylate cyclase 1 receptors modulate nociceptive behaviors in both inflammatory and neuropathic pain states.

Davis-Taber R, Baker S, Lehto SG, Zhong C, Surowy CS, Faltynek CR, Scott VE, Honore P.

J Pain. 2008 May;9(5):449-56. doi: 10.1016/j.jpain.2008.01.329. Epub 2008 Mar 12.

PMID:
18337184
16.

Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management.

Gomtsyan A, Bayburt EK, Schmidt RG, Surowy CS, Honore P, Marsh KC, Hannick SM, McDonald HA, Wetter JM, Sullivan JP, Jarvis MF, Faltynek CR, Lee CH.

J Med Chem. 2008 Feb 14;51(3):392-5. doi: 10.1021/jm701007g. Epub 2008 Jan 10.

PMID:
18183945
17.

[3H]A-585539 [(1S,4S)-2,2-dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1]heptane], a novel high-affinity alpha7 neuronal nicotinic receptor agonist: radioligand binding characterization to rat and human brain.

Anderson DJ, Bunnelle W, Surber B, Du J, Surowy C, Tribollet E, Marguerat A, Bertrand D, Gopalakrishnan M.

J Pharmacol Exp Ther. 2008 Jan;324(1):179-87. Epub 2007 Oct 24.

PMID:
17959745
18.

Synthesis and structure-activity relationship studies of 3,6-diazabicyclo[3.2.0]heptanes as novel alpha4beta2 nicotinic acetylcholine receptor selective agonists.

Ji J, Schrimpf MR, Sippy KB, Bunnelle WH, Li T, Anderson DJ, Faltynek C, Surowy CS, Dyhring T, Ahring PK, Meyer MD.

J Med Chem. 2007 Nov 1;50(22):5493-508. Epub 2007 Oct 11.

PMID:
17929796
19.

[3H]A-778317 [1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand for the human transient receptor potential vanilloid-1 (TRPV1) receptor.

Bianchi BR, El Kouhen R, Neelands TR, Lee CH, Gomtsyan A, Raja SN, Vaidyanathan SN, Surber B, McDonald HA, Surowy CS, Faltynek CR, Moreland RB, Jarvis MF, Puttfarcken PS.

J Pharmacol Exp Ther. 2007 Oct;323(1):285-93. Epub 2007 Jul 27.

PMID:
17660385
20.

Structure-activity studies and analgesic efficacy of N-(3-pyridinyl)-bridged bicyclic diamines, exceptionally potent agonists at nicotinic acetylcholine receptors.

Bunnelle WH, Daanen JF, Ryther KB, Schrimpf MR, Dart MJ, Gelain A, Meyer MD, Frost JM, Anderson DJ, Buckley M, Curzon P, Cao YJ, Puttfarcken P, Searle X, Ji J, Putman CB, Surowy C, Toma L, Barlocco D.

J Med Chem. 2007 Jul 26;50(15):3627-44. Epub 2007 Jun 22.

PMID:
17585748
21.

Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher efficacy in inflammatory pain model.

Gomtsyan A, Bayburt EK, Keddy R, Turner SC, Jinkerson TK, Didomenico S, Perner RJ, Koenig JR, Drizin I, McDonald HA, Surowy CS, Honore P, Mikusa J, Marsh KC, Wetter JM, Faltynek CR, Lee CH.

Bioorg Med Chem Lett. 2007 Jul 15;17(14):3894-9. Epub 2007 May 3.

PMID:
17507218
22.

Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets.

Zhang D, Saraf A, Kolasa T, Bhatia P, Zheng GZ, Patel M, Lannoye GS, Richardson P, Stewart A, Rogers JC, Brioni JD, Surowy CS.

Neuropharmacology. 2007 Mar;52(4):1095-105. Epub 2007 Jan 9.

PMID:
17217969
23.

High- and low-sensitivity subforms of alpha4beta2 and alpha3beta2 nAChRs.

Briggs CA, Gubbins EJ, Putman CB, Thimmapaya R, Meyer MD, Surowy CS.

J Mol Neurosci. 2006;30(1-2):11-2.

PMID:
17192606
24.

Synthesis and structure-activity relationships of 3,8-diazabicyclo[4.2.0]octane ligands, potent nicotinic acetylcholine receptor agonists.

Frost JM, Bunnelle WH, Tietje KR, Anderson DJ, Rueter LE, Curzon P, Surowy CS, Ji J, Daanen JF, Kohlhaas KL, Buckley MJ, Henry RF, Dyhring T, Ahring PK, Meyer MD.

J Med Chem. 2006 Dec 28;49(26):7843-53.

PMID:
17181167
25.

A high throughput fluorescent assay for measuring the activity of fatty acid amide hydrolase.

Kage KL, Richardson PL, Traphagen L, Severin J, Pereda-Lopez A, Lubben T, Davis-Taber R, Vos MH, Bartley D, Walter K, Harlan J, Solomon L, Warrior U, Holzman TF, Faltynek C, Surowy CS, Scott VE.

J Neurosci Methods. 2007 Mar 30;161(1):47-54. Epub 2006 Nov 2.

PMID:
17083980
26.

Untranslated region-dependent exclusive expression of high-sensitivity subforms of alpha4beta2 and alpha3beta2 nicotinic acetylcholine receptors.

Briggs CA, Gubbins EJ, Marks MJ, Putman CB, Thimmapaya R, Meyer MD, Surowy CS.

Mol Pharmacol. 2006 Jul;70(1):227-40. Epub 2006 Mar 28.

PMID:
16569710
27.

Acidification of rat TRPV1 alters the kinetics of capsaicin responses.

Neelands TR, Jarvis MF, Han P, Faltynek CR, Surowy CS.

Mol Pain. 2005 Sep 28;1:28.

28.

Distribution and functional characterization of human Nav1.3 splice variants.

Thimmapaya R, Neelands T, Niforatos W, Davis-Taber RA, Choi W, Putman CB, Kroeger PE, Packer J, Gopalakrishnan M, Faltynek CR, Surowy CS, Scott VE.

Eur J Neurosci. 2005 Jul;22(1):1-9.

PMID:
16029190
29.

A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel and selective transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid.

El Kouhen R, Surowy CS, Bianchi BR, Neelands TR, McDonald HA, Niforatos W, Gomtsyan A, Lee CH, Honore P, Sullivan JP, Jarvis MF, Faltynek CR.

J Pharmacol Exp Ther. 2005 Jul;314(1):400-9. Epub 2005 Apr 18.

PMID:
15837819
30.

Loss of functional neuronal nicotinic receptors in dorsal root ganglion neurons in a rat model of neuropathic pain.

Dubé GR, Kohlhaas KL, Rueter LE, Surowy CS, Meyer MD, Briggs CA.

Neurosci Lett. 2005 Mar 7;376(1):29-34. Epub 2004 Dec 8.

PMID:
15694269
31.

Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties.

Gomtsyan A, Bayburt EK, Schmidt RG, Zheng GZ, Perner RJ, Didomenico S, Koenig JR, Turner S, Jinkerson T, Drizin I, Hannick SM, Macri BS, McDonald HA, Honore P, Wismer CT, Marsh KC, Wetter J, Stewart KD, Oie T, Jarvis MF, Surowy CS, Faltynek CR, Lee CH.

J Med Chem. 2005 Feb 10;48(3):744-52.

PMID:
15689158
32.

Different nicotinic acetylcholine receptor subtypes mediating striatal and prefrontal cortical [3H]dopamine release.

Cao YJ, Surowy CS, Puttfarcken PS.

Neuropharmacology. 2005 Jan;48(1):72-9.

PMID:
15617729
33.

Nicotinic acetylcholine receptor-mediated [3H]dopamine release from hippocampus.

Cao YJ, Surowy CS, Puttfarcken PS.

J Pharmacol Exp Ther. 2005 Mar;312(3):1298-304. Epub 2004 Nov 12.

PMID:
15542623
34.

Mechanism of action of A-85380 in an animal model of depression.

Buckley MJ, Surowy C, Meyer M, Curzon P.

Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):723-30.

PMID:
15276699
35.

Peripheral and central sites of action for A-85380 in the spinal nerve ligation model of neuropathic pain.

Rueter LE, Kohlhaas KL, Curzon P, Surowy CS, Meyer MD.

Pain. 2003 Jun;103(3):269-76.

PMID:
12791433
36.

TH1 and TH2 cytokine inhibition by 3,5-bis(trifluoromethyl)pyrazoles, a novel class of immunomodulators.

Chen Y, Smith ML, Chiou GX, Ballaron S, Sheets MP, Gubbins E, Warrior U, Wilkins J, Surowy C, Nakane M, Carter GW, Trevillyan JM, Mollison K, Djuric SW.

Cell Immunol. 2002 Dec;220(2):134-42.

PMID:
12657248
37.

Differential regulation of nicotinic receptor-mediated neurotransmitter release following chronic (-)-nicotine administration.

Jacobs I, Anderson DJ, Surowy CS, Puttfarcken PS.

Neuropharmacology. 2002 Oct;43(5):847-56.

PMID:
12384170
38.

Direct interaction of STAT4 with the IL-12 receptor.

Yao BB, Niu P, Surowy CS, Faltynek CR.

Arch Biochem Biophys. 1999 Aug 1;368(1):147-55.

PMID:
10415122
39.

Functional characterization of novel IL-2 transcriptional inhibitors.

Baine Y, Stankunas BM, Miller P, Hobbs C, Tiberio L, Koch J, Yoon K, Sawutz D, Surowy C.

J Immunol. 1995 Apr 15;154(8):3667-77.

PMID:
7706710
40.

Human U1-70K ribonucleoprotein antigen gene: organization, nucleotide sequence, and mapping to locus 19q13.3.

Spritz RA, Strunk K, Surowy CS, Mohrenweiser HW.

Genomics. 1990 Oct;8(2):371-9.

PMID:
2147422
41.

The human RD protein is closely related to nuclear RNA-binding proteins and has been highly conserved.

Surowy CS, Hoganson G, Gosink J, Strunk K, Spritz RA.

Gene. 1990 Jun 15;90(2):299-302.

PMID:
2119325
42.

Direct, sequence-specific binding of the human U1-70K ribonucleoprotein antigen protein to loop I of U1 small nuclear RNA.

Surowy CS, van Santen VL, Scheib-Wixted SM, Spritz RA.

Mol Cell Biol. 1989 Oct;9(10):4179-86.

43.

The human U1-70K snRNP protein: cDNA cloning, chromosomal localization, expression, alternative splicing and RNA-binding.

Spritz RA, Strunk K, Surowy CS, Hoch SO, Barton DE, Francke U.

Nucleic Acids Res. 1987 Dec 23;15(24):10373-91.

44.

Poly(ADP-ribose) polymerase activity in proliferating and quiescent murine mammary carcinoma cells.

Sweiger SE, Petzold SJ, Surowy CS, Berger SJ, Dethlefsen LA, Berger NA.

Radiat Res. 1986 Feb;105(2):219-26.

PMID:
3081939
45.

A 3-aminobenzamide-resistant labeled protein in [32P]NAD+-labeled cells.

Surowy CS, Berger NA.

Biochim Biophys Acta. 1985 Dec 12;847(3):309-15.

PMID:
3933575
47.

Nucleotide-stimulated proteolysis of histone H1.

Surowy CS, Berger NA.

Proc Natl Acad Sci U S A. 1983 Sep;80(18):5510-4.

48.

Unique acceptors for poly(ADP-ribose) in resting, proliferating and DNA-damaged human lymphocytes.

Surowy CS, Berger NA.

Biochim Biophys Acta. 1983 May 20;740(1):8-18.

PMID:
6849930
49.
50.

Application of aminoethylcellulose-chromatographic separation of monomeric and polymeric ADP-ribose.

Purnell MR, Stone PR, Surowy CS, Whish WJ.

Biochem Soc Trans. 1981 Feb;9(1):119-20. No abstract available.

PMID:
7225189

Supplemental Content

Loading ...
Support Center